Evidence map›Paper›PMID 27485029›Full record

ArticleAlimentary pharmacology & therapeutics2016

Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry.

A Rubio-Tapia, G Malamut, W H M Verbeek, R L J van Wanrooij, D A Leffler, S I Niveloni, C Arguelles-Grande, B D Lahr, A R Zinsmeister, J A Murray and 6 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03866538 (Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03866538 phase4terminatednot on this mapstarted 2019, after this paper: background citation

Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies

TypeinterventionalSponsorMayo ClinicRan2019 to 2021Enrolled1ConditionsEnteropathy, Celiac Disease, CVID Enteropathy, Collagenous SprueArmsWithdrawal of Oral Budesonide
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Dietary assessments in individuals living with coeliac disease: key considerations.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Review
  6. Review
  7. Celiac Disease in the Elderly.Current treatment options in gastroenterology · 2022
    Article
  8. The global burden of coeliac disease: opportunities and challenges.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  9. Article
  10. Refractory Celiac Disease.Current gastroenterology reports · 2020
    Review
  11. Diagnosis and Treatment Patterns in Celiac Disease.Digestive diseases and sciences · 2019
    Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

A Rubio-TapiaMayo Clinic, Rochester, MN, USA.
G MalamutHopital Europeen Georges-Pompidou, Paris, France.
W H M VerbeekVU University Medical Centre, Amsterdam, The Netherlands.
R L J van WanrooijVU University Medical Centre, Amsterdam, The Netherlands.
D A LefflerBeth Israel Deaconess Medical Center, Boston, MA, USA.
S I NiveloniHospital Dr. Carlos Nonorino Udaondo, Buenos Aires, Argentina.
C Arguelles-GrandeColumbia University Medical Center, New York, NY, USA.
B D LahrMayo Clinic, Rochester, MN, USA.
A R ZinsmeisterMayo Clinic, Rochester, MN, USA.
J A MurrayMayo Clinic, Rochester, MN, USA.
C P KellyBeth Israel Deaconess Medical Center, Boston, MA, USA.
J C BaiHospital Dr. Carlos Nonorino Udaondo, Buenos Aires, Argentina.
P H GreenColumbia University Medical Center, New York, NY, USA.
S DaumCharite-University Medicine Berlin, Berlin, Germany.
C J J MulderVU University Medical Centre, Amsterdam, The Netherlands.
C CellierHopital Europeen Georges-Pompidou, Paris, France.

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
EPIDEMIOLOGY OF CELIAC DISEASE--A POPULATION BASED STUDYR01DK057892 · NIDDK · MAYO CLINIC ROCHESTER · PI MURRAY, JOSEPH A · 2000 to 2010
$3.9M
NCATS NIH HHS UL1 TR000135NIDDK NIH HHS R01 DK057892
6 · The paper itself

Abstract

backgroundRefractory coeliac disease is a severe complication of coeliac disease with heterogeneous outcome.

aimTo create a prognostic model to estimate survival of patients with refractory coeliac disease.

methodsWe evaluated predictors of 5-year mortality using Cox proportional hazards regression on subjects from a multinational registry. Bootstrap resampling was used to internally validate the individual factors and overall model performance. The mean of the estimated regression coefficients from 400 bootstrap models was used to derive a risk score for 5-year mortality.

resultsThe multinational cohort was composed of 232 patients diagnosed with refractory coeliac disease across seven centres (range of 11-63 cases per centre). The median age was 53 years and 150 (64%) were women. A total of 51 subjects died during a 5-year follow-up (cumulative 5-year all-cause mortality = 30%). From a multiple variable Cox proportional hazards model, the following variables were significantly associated with 5-year mortality: age at refractory coeliac disease diagnosis (per 20 year increase, hazard ratio = 2.21; 95% confidence interval, CI: 1.38-3.55), abnormal intraepithelial lymphocytes (hazard ratio = 2.85; 95% CI: 1.22-6.62), and albumin (per 0.5 unit increase, hazard ratio = 0.72; 95% CI: 0.61-0.85). A simple weighted three-factor risk score was created to estimate 5-year survival.

conclusionsUsing data from a multinational registry and previously reported risk factors, we create a prognostic model to predict 5-year mortality among patients with refractory coeliac disease. This new model may help clinicians to guide treatment and follow-up.

Indexed as

Models, StatisticalAdolescentAdultAgedAged, 80 and overCeliac DiseaseFemaleHumansLymphocytesMaleMiddle AgedPrognosisProportional Hazards ModelsRegistriesRisk FactorsYoung Adult

Identifiers

PMID27485029
PMCPMC5018234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.